Cap-Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug Target

Medicinal Research Reviews

Volumn 32, Issue 4, 2012, Pages 786-814

  Jia, Yan ^a,c   Polunovsky, Vitaly ^b   Bitterman, Peter B ^b   Wagner, Carston R ^a,b  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anticancer; EIF4E; Translation

Indexed keywords

4EE1RCAT; 4EGI 1; 4EGI 1A; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BINDING PROTEIN; CAPPED RNA; CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; FIREFLY LUCIFERASE; FLICE INHIBITORY PROTEIN; GUANOSINE DIPHOSPHATE; GUANOSINE PHOSPHATE; INITIATION FACTOR 4E; INITIATION FACTOR 4G; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NUCLEOTIDE BINDING PROTEIN; PREDNISOLONE; RAPAMYCIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RENILLA LUCIFERIN 2 MONOOXYGENASE; RIBAVIRIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE SULFATE;

5' UNTRANSLATED REGION; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN 3T3; CELL VIABILITY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG TARGETING; EMBRYO DEVELOPMENT; FLUORESCENCE; FLUORESCENCE POLARIZATION IMMUNOASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE OVEREXPRESSION; GLIOBLASTOMA; HEPATITIS C; HIGH THROUGHPUT SEQUENCING; HUMAN; INTERNAL RIBOSOME ENTRY SITE; LASSA FEVER; LEUKEMIA CELL LINE; LUNG CANCER; LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ONCOGENE; PH; PROTEIN CROSS LINKING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RNA TRANSLATION; SEVERE ACUTE RESPIRATORY SYNDROME; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSLATION INITIATION; ULTRAVIOLET RADIATION; ZEBRA FISH;

ANIMALS; ANTINEOPLASTIC AGENTS; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN BIOSYNTHESIS; RNA CAPS; RNA, MESSENGER;

EID: 84863838830     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21260     Document Type: Review

References (132)

1. Gilbert RJ, Gordiyenko Y, von der Haar T, Sonnen AF, Hofmann G, Nardelli M, Stuart DI, McCarthy JE. Reconfiguration of yeast 40Sribosomal subunit domains by the translation initiation multifactor complex. Proc Natl Acad Sci USA 2007;104:5788-5793.
2. Merrick WC. Cap-dependent and cap-independent translation in eukaryotic systems. Gene 2004;332:1-11.
3. Svitkin YV, Herdy B, Costa-Mattioli M, Gingras AC, Raught B, Sonenberg N. Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol Cell Biol 2005;25:10556-10565.
4. Lopez-Lastra M, Rivas A, Barria MI. Protein synthesis in eukaryotes: The growing biological relevance of cap-independent translation initiation. Biol Res 2005;38:121-146.
5. Tumminia SJ, Hellmann W, Wall JS, Boublik M. Image analysis of Artemia salina ribosomes by scanning transmission electron microscopy. J Struct Biol 1992;109:109-115.
6. Merrick WC. Initiation of protein biosynthesis in eukaryotes. Biochem Mol Biol Educ 2003;31:378-385.
7. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-963.
8. Gallie DR. Protein-protein interactions required during translation. Plant Mol Biol 2002;50:949-970.
9. Browning KS. The plant translational apparatus. Plant Mol Biol 1996;32:107-144.
10. Gallie DR. A tale of two termini: A functional interaction between the termini of an mRNA is a prerequisite for efficient translation initiation. Gene 1998;216:1-11.
11. Rogers GW, Jr, Richter NJ, Lima WF, Merrick WC. Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F. J Biol Chem 2001;276:30914-30922.
12. De Benedetti A, Rhoads RE. Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc Natl Acad Sci USA 1990;87:8212-8216.
13. Polunovsky VA, Bitterman PB. The cap-dependent translation apparatus integrates and amplifies cancer pathways. RNA Biol 2006;3:10-17.
14. Hershey JWB, Merrick WC. The pathway and mechanism of initiation of protein synthesis. Translational control of gene expression. In: Sonnenberg, N. Hershey, JWR Matthews, MB Ed. Cold Spring Harbor, NY: Cold Spring Harbor Press; 2000. p 33-88.
15. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189-3199.
16. Nathan CO, Carter P, Liu L, Li BD, Abreo F, Tudor A, Zimmer SG, De Benedetti A. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 1997;15:1087-1094.
17. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10:484-486.
18. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhas O, Shokat KM, Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010;17:249-261.
19. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-337.
20. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004;5:553-563.
21. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007;117:2638-2648.
22. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, Halperin JA, Wagner G. Small molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007;128:257-267.
23. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, Brem B, Greger H, Lowe SW, Porco JA, Jr, Pelletier J. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008;118:2651-2660.
24. Koromilas AE, Lazaris-Karatzas A, Sonenberg N. mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J 1992;11:4153-4158.
25. De Benedetti A, Harris AL. eIF4E expression in tumors: Its possible role in progression of malignancies. Int J Biochem Cell Biol 1999;31:59-72.
26. Bitterman Peter B., Polunovsky Vitaly A. Translational Control of Cancer: Implications for Targeted Therapy. In: Polunovsky VA, Houghton PJ. Eds., Cancer Drug Discovery and Development. Humana Press Inc., Totowa, NJ, USA, 2010, pp. 237-255.
27. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008;68:631-634.
28. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-6422.
29. Larsson O, Li S, Issaenko OA, Avdulov S, Peterson M, Smith K, Bitterman PB, Polunovsky VA. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res 2007;67:6814-6824.
30. Li BDL, Liu L, Dawson M, Benedetti AD. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 1997;79:2385-2390.
31. Watkins SJ, Norbury CJ. Translation initiation and its deregulation during tumorigenesis. Br J Cancer 2002;86:1023-1027.
32. Rong L, Livingstone M, Sukarieh R, Petroulakis E, Gingras AC, Crosby K, Smith B, Polakiewicz RD, Pelletier J, Ferraiuolo MA, Sonenberg N. Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA 2008;14:1318-1327.
33. Poulin F, Gingras AC, Olsen H, Chevalier S, Sonenberg N. 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J Biol Chem 1998;273:14002-14007.
34. Raught B, Gingras AC. eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol 1999;31:43-57.
35. Joshi B, Cai AL, Keiper BD, Minich WB, Mendez R, Beach CM, Stepinski J, Stolarski R, Darzynkiewicz E, Rhoads RE. Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J Biol Chem 1995;270:14597-14603.
36. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 1999;19:1871-1880.
37. Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: The mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000;20:1343-1351.
38. Li S, Sonenberg N, Gingras A, Peterson M, Avdulov S, Polunovsky VA, Bitterman PB. Translational control of cell fate: Availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol Cell Biol 2002;22:2853-2861.
39. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: Implications for cancer and anticancer therapy. Br J Cancer 2006;94:195-199.
40. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A, Meric-Bernstam F. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 2008;7:1782-1788.
41. Graber TE, Holcik M. Cap-independent regulation of gene expression in apoptosis. Mol Biosyst 2007;3:825-834.
42. Spriggs KA, Stoneley M, Bushell M, Willis AE. Re-programming of translation following cell stress allows IRES-mediated translation to predominate. Biol Cell 2008;100:27-38.
43. Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, Simon MC. Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem 2008;283:16309-16319.
44. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-7058.
45. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997;16:1909-1920.
46. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010;10:254-266.
47. Silva RL, Wendel HG. MNK, EIF4E and targeting translation for therapy. Cell Cycle 2008;7:553-555.
48. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, Lowe SW. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007;21:3232-3237.
49. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA 2010;107:14134-14139.
50. Scheper GC, van Kollenburg B, Hu J, Luo Y, Goss DJ, Proud CG. Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA. J Biol Chem 2002;277:3303-3309.
51. Fan S, Li Y, Yue P, Khuri FR, Sun SY. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia 2010;12:346-356.
52. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, Lowe SW. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007;21:3232-3237.
53. Marcotrigiano J, Gingras A, Sonenberg N, Burley SK. Cocrystal structure of the messenger RNA 5' cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 1997;89:951-961.
54. Matsuo H, Li HJ, McGuire AM, Fletcher CM, Gingras AC, Sonenberg N, Wagner G. Structure of translation factor eIF4E bound to m(7)GDP and interaction with 4E-binding protein. Nat Struct Biol 1997;4:717-724.
55. Brown CJ, McNae I, Fischer PM, Walkinshaw MD. Crystallographic and mass spectrometric characterisation of eIF4E with N7-alkylated cap derivatives. J Mol Biol 2007;372:7-15.
56. Tomoo K, Matsushita Y, Fujisaki H, Abiko F, Shen X, Taniguchi T, Miyagawa H, Kitamura K, Miura K, Ishida T. Structural basis for mRNA cap-binding regulation of eukaryotic initiation factor 4E by 4E-binding protein, studied by spectroscopic, X-ray crystal structural, and molecular dynamics simulation methods. Biochim Biophys Acta 2005;1753:191-208.
57. Niedzwiecka A, Marcotrigiano J, Stepinski J, Jankowska-Anyszka M, Wyslouch-Cieszynska A, Dadlez M, Gingras AC, Mak P, Darzynkiewicz E, Sonenberg N, Burley SK, Stolarski R. Biophysical studies of eIF4E cap-binding protein: Recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins. J Mol Biol 2002;319:615-635.
58. Tomoo K, Shen X, Okabe K, Nozoe Y, Fukuhara S, Morino S, Ishida T, Taniguchi T, Hasegawa H, Terashima A, Sasaki M, Katsuya Y, Kitamura K, Miyoshi H, Ishikawa M, Miura K. Crystal structures of 7-methylguanosine 5'-triphosphate (m(7)GTP)- and P(1)-7-methylguanosine-P(3)-adenosine-5′, 5′-triphosphate (m(7)GpppA)-bound human full-length eukaryotic initiation factor 4E: Biological importance of the C-terminal flexible region. Biochem J 2002;362:539-544.
59. Cai A, Jankowska-Anyszka M, Centers A, Chlebicka L, Stepinski J, Stolarski R, Darzynkiewicz E, Rhoads RE. Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation. Biochem. 1999;38:8538-8547.
60. Joshi B, Lee K, Maeder DL, Jagus R. Phylogenetic analysis of eIF4E-family members. BMC Evol Biol 2005;5:48. doi: 10.1186/1471-2148-5-48.
61. Rosettani P, Knapp S, Vismara MG, Rusconi L, Cameron AD. Structures of the human eIF4E homologous protein, h4EHP, in its m7GTP-bound and unliganded forms. J Mol Biol 2007;368:691-705.
62. Joshi B, Cameron A, Jagus R. Characterization of mammalian eIF4E-family members. Eur J Biochem 2004;271:2189-2203.
63. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Mol Cell 1999;3:707-716.
64. Niedzwiecka A, Stepinski J, Darzynkiewicz E, Sonenberg N, Stolarski R. Positive heat capacity change upon specific binding of translation initiation factor eIF4E to mRNA 5' cap. Biochemistry 2002;41:12140-12148.
65. Slepenkov SV, Darzynkiewicz E, Rhoads RE. Stopped-flow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides: Evidence for a one-step binding mechanism. J Biol Chem 2006;281:14927-14938.
66. Blachut-Okrasinska E, Bojarska E, Niedzwiecka A, Chlebicka L, Darzynkiewicz E, Stolarski R, St Pinski J, Antosiewicz JM. Stopped-flow and Brownian dynamics studies of electrostatic effects in the kinetics of binding of 7-methyl-GpppG to the protein eIF4E. Eur Biophys J 2000;29:487-498.
67. Dlugosz M, Blachut-Okrasinska E, Bojarska E, Darzynkiewicz E, Antosiewicz JM. Effects of pH on kinetics of binding of mRNA-cap analogs by translation initiation factor eIF4E. Eur Biophys J 2003;31:608-616.
68. Slepenkov SV, Korneeva NL, Rhoads RE. Kinetic mechanism for assembly of the m7GpppG.eIF4E.eIF4G complex. J Biol Chem 2008;283:25227-25237.
69. Zuberek J, Jemielity J, Jablonowska A, Stepinski J, Dadlez M, Stolarski R, Darzynkiewicz E. Influence of electric charge variation at residues 209 and 159 on the interaction of eIF4E with the mRNA 5' terminus. Biochemistry 2004;43:5370-5379.
70. Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. RNA 2001;7:1486-1495.
71. Carberry SE, Goss DJ. Wheat germ initiation factors 4F and (iso)4F interact differently with oligoribonucleotide analogues of rabbit alpha-globin mRNA. Biochemistry 1991;30:4542-4545.
72. Goss DJ, Carberry SE, Dever TE, Merrick WC, Rhoads RE. A fluorescence study of the interaction of protein synthesis initiation factors 4A, 4E, and 4F with mRNA and oligonucleotide analogs. Biochim Biophys Acta 1990;1050:163-166.
73. Jemielity J, Fowler T, Zuberek J, Stepinski J, Lewdorowicz M, Niedzwiecka A, Stolarski R, Darzynkiewicz E, Rhoads RE. Novel "anti-reverse" cap analogs with superior translational properties. RNA 2003;9:1108-1122.
74. Haghighat A, Sonenberg N. eIF4G dramatically enhances the binding of eIF4E to the mRNA 5'-cap structure. J Biol Chem 1997;272:21677-21680.
75. Friedland DE, Wooten WN, LaVoy JE, Hagedorn CH, Goss DJ. A mutant of eukaryotic protein synthesis initiation factor eIF4E(K119A) has an increased binding affinity for both m7G cap analogues and eIF4G peptides. Biochemistry 2005;44:4546-4550.
76. Gross JD, Moerke NJ, von der Haar T, Lugovskoy AA, Sachs AB, McCarthy JE, Wagner G. Ribosome loading onto the mRNA cap is driven by conformational coupling between eIF4G and eIF4E. Cell 2003;115:739-750.
77. Ptushkina M, von der Haar T, Vasilescu S, Frank R, Birkenhager R, McCarthy JE. Cooperative modulation by eIF4G of eIF4E-binding to the mRNA 5' cap in yeast involves a site partially shared by p20. EMBO J 1998;17:4798-4808.
78. von Der Haar T, Ball PD, McCarthy JE. Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5'-cap by domains of eIF4G. J Biol Chem 2000;275:30551-30555.
79. Darzynkiewicz E, Stepinski J, Ekiel I, Goyer C, Sonenberg N, Temeriusz A, Jin Y, Sijuwade T, Haber D, Tahara SM. Inhibition of eukaryotic translation by nucleoside 5'-monophosphate analogues of mRNA 5'-cap: Changes in N7 substituent affect analogue activity. Biochemistry 1989;28:4771-4778.
80. Darzynkiewicz E, Ekiel I, Lassota P, Tahara SM. Inhibition of eukaryotic translation by analogues of messenger RNA 5'-cap: Chemical and biological consequences of 5'-phosphate modifications of 7-methylguanosine 5'-monophosphate. Biochemistry 1987;26:4372-4380.
81. Ghosh P, Park C, Peterson MS, Bitterman PB, Polunovsky VA, Wagner CR. Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-methyl GTP. Bioorg Med Chem Lett 2005;15:2177-2180.
82. Jia Y, Chiu TL, Amin EA, Polunovsky V, Bitterman PB, Wagner CR. Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP. Eur J Med Chem 2010;45:1304-1313.
83. Wagner CR, Iyer VV, McIntee EJ. Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides. Med Res Rev 2000;20:417-451.
84. Wagner CR, Chang SL, Griesgraber GW, Song H, McIntee EJ, Zimmerman CL. Antiviral nucleoside drug delivery via amino acid phosphoramidates. Nucleosides Nucleotides 1999;18:913-919.
85. Chang S, Griesgraber GW, Southern PJ, Wagner CR. Amino acid phosphoramidate monoesters of 3'-azido-3'-deoxythymidine: Relationship between antiviral potency and intracellular metabolism. J Med Chem 2001;44:223-231.
86. McGuigan C, Harris SA, Daluge SM, Gudmundsson KS, McLean EW, Burnette TC, Marr H, Hazen R, Condreay LD, Johnson L, De Clercq E, Balzarini J. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. J Med Chem 2005;48:3504-3515.
87. Song H, Griesgraber GW, Wagner CR, Zimmerman CL. Pharmacokinetics of amino acid phosphoramidate monoesters of zidovudine in rats. Antimicrob Agents Chemother 2002;46:1357-1363.
88. Song H, Johns R, Griesgraber GW, Wagner CR, Zimmerman CL. Disposition and oral bioavailability in rats of an antiviral and antitumor amino acid phosphoramidate prodrug of AZT-monophosphate. Pharm Res 2003;20:448-451.
89. Ghosh B, Benyumov AO, Ghosh P, Jia Y, Avdulov S, Dahlberg PS, Peterson M, Smith K, Polunovsky VA, Bitterman PB, Wagner CR. Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol 2009;4:367-377.
90. Goossens K, Van Soom A, Van Poucke M, Vandaele L, Vandesompele J, Van Zeveren A, Peelman LJ. Identification and expression analysis of genes associated with bovine blastocyst formation. BMC Dev Biol 2007;7:64. doi: 10.1186/1471-213X-7-64.
91. De Clercq E. Antiviral agents: Characteristic activity spectrum depending on the molecular target with which they interact. Adv Virus Res 1993;42:1-55.
92. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide. Science 1972;177:705-706.
93. Tam RC, Lau JY, Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 2001;12:261-272.
94. Picardi A, Gentilucci UV, Zardi EM, D'Avola D, Amoroso A, Afeltra A. The role of ribavirin in the combination therapy of hepatitis C virus infection. Curr Pharm Des 2004;10:2081-2092.
95. Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. Ribavirin mode of action in chronic hepatitis C: From clinical use back to molecular mechanisms. Liver Int 2008;28:1332-1343.
96. Miller JP, Kigwana LJ, Streeter DG, Robins RK, Simon LN, Roboz J. The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann N Y Acad Sci 1977;284:211-229.
97. Page T, Connor JD. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem 1990;22:379-383.
98. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN. Mechanism of action of 1-PD-ribofuranosyl-1, 2, 4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 1973;70:1174-1178.
99. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-1379.
100. Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001;276:46094-46098.
101. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: Direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001;98:6895-6900.
102. Goswami BB, Borek E, Sharma OK, Fujitaki J, Smith RA. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun 1979;89:830-836.
103. Bougie I, Bisaillon M. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem 2004;279:22124-22130.
104. Muller WE, Maidhof A, Taschner H, Zahn RK. Virazole (1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide; a cytostatic agent. Biochem Pharmacol 1977;26:1071-1075.
105. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA 2004;101:18105-18110.
106. Yan Y, Svitkin Y, Lee JM, Bisaillon M, Pelletier J. Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. RNA 2005;11:1238-1244.
107. Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, Borden KL. Further evidence that ribavirin interacts with eIF4E. RNA 2005;11:1762-1766.
108. Carberry SE, Rhoads RE, Goss DJ. A spectroscopic study of the binding of m7GTP and m7GpppG to human protein synthesis initiation factor 4E. Biochemistry 1989;28:8078-8083.
109. Kentsis A, Dwyer EC, Perez JM, Sharma M, Chen A, Pan ZQ, Borden KL. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. J Mol Biol 2001;312:609-623.
110. Westman B, Beeren L, Grudzien E, Stepinski J, Worch R, Zuberek J, Jemielity J, Stolarski R, Darzynkiewicz E, Rhoads RE, Preiss T. The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. RNA 2005;11:1505-1513.
111. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH, Jr, Borden KL. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): A proof-of-principle clinical trial with ribavirin. Blood 2009;114:257-260.
112. Barnhart BC, Lam JC, Young RM, Houghton PJ, Keith B, Simon MC. Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival. Cancer Biol Ther 2008;7:1441-1449.
113. Brandi L, Fabbretti A, La Teana A, Abbondi M, Losi D, Donadio S, Gualerzi CO. Specific, efficient, and selective inhibition of prokaryotic translation initiation by a novel peptide antibiotic. Proc Natl Acad Sci USA 2006;103:39-44.
114. Novac O, Guenier AS, Pelletier J. Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res 2004;32:902-915.
115. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-339.
116. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010;28:2839-2846.
117. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: Up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007;6:1387-1399.
118. Barua S, Linton RS, Gamboa J, Banerjee I, Yarmush ML, Rege K. Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists. Cancer Lett 2010;293:240-253.
119. Su RY, Chao Y, Chen TY, Huang DY, Lin WW. 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol Cancer Ther 2007;6:1562-1571.
120. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non-small cell lung cancer cells: Sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007;6:2103-2112.
121. Panner A, Parsa AT, Pieper RO. Translational regulation of TRAIL sensitivity. Cell Cycle 2006;5:147-150.
122. Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005;25:8809-8823.
123. Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, Qui M, Lewis I, Kurtkaya S, Dingledine R, Fu H, Kozakov D, Vajda S, Pelletier J. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci USA 2011;108:1046-1051.
124. Rocak S, Linder P. DEAD-box proteins: The driving forces behind RNA metabolism. Nat Rev Mol Cell Biol 2004;5:232-241.
125. Ko SY, Guo H, Barengo N, Naora H. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res 2009;15:4336-4347.
126. Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003;22:9087-9096.
127. Mani S, Rudin CM, Kunkel K, Holmlund JT, Geary RS, Kindler HL, Dorr FA, Ratain MJ. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res 2002;8:1042-1048.
128. Zangemeister-Wittke U, Leech SH, Olie RA, Simoes-Wust AP, Gautschi O, Luedke GH, Natt F, Haner R, Martin P, Hall J, Nalin CM, Stahel RA. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000;6:2547-2555.
129. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, Dean NM. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000;18:862-867.
130. Yu RZ, Geary RS, Monteith DK, Matson J, Truong L, Fitchett J, Levin AA. Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci 2004;93:48-59.
131. Crooke ST. Progress in antisense therapeutics. Med Res Rev 1996;16:319-344.
132. Dong K, Wang R, Wang X, Lin F, Shen JJ, Gao P, Zhang HZ. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat 2009;113:443-456.